Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00120887 · ClinicalTrials.gov registry record · Phase 4
Lupus Atherosclerosis Prevention Study
A Phase 4 study of Systemic Lupus Erythematosus, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT00120887 is a Phase 4 study of Systemic Lupus Erythematosus that has completed, run by Johns Hopkins University. The registered enrollment target is 200 participants, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00120887, a Phase 4 study of Systemic Lupus Erythematosus, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Cardiovascular disease, specifically from atherosclerosis, is the major cause of mortality in systemic lupus erythematosus (SLE) in developed countries. Coronary artery disease and stroke contribute to long-term morbidity in surviving patients. Atherosclerosis in SLE is multifactorial, with immune/inflammatory endothelial damage, traditional cardiovascular risk factors, and prothrombotic factors all playing important roles. Multiple groups have shown that hyperlipidemia is predictive of later atherosclerosis in SLE. In the general population, statins have become the drug of choice in preventing atherosclerotic events, through two mechanisms: lipid lowering that helps to prevent progression, and stabilization of plaques to prevent rupture. In the Lupus Atherosclerosis Prevention Trial we will determine if atorvastatin reduces the progression of atherosclerosis on helical computed tomography (CT) and carotid duplex. Recent work has confirmed that statins have an immunomodulatory role. This study will also determine whether statins improve clinical lupus activity or lupus serologies (anti-dsDNA and complement).
Conditions Studied
Interventions
- DRUG Atorvastatin
Study Locations (1)
Maryland
- Johns Hopkins Lupus Center 1830 E Monument Street, Ste 7500 - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2002-04 |
| Est. Completion | 2005-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00120887
The ClinicalTrials.gov registry entry for NCT00120887 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (47% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin is the first listed.
NCT00120887 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00120887 about?
NCT00120887 is a clinical study titled "Lupus Atherosclerosis Prevention Study". Cardiovascular disease, specifically from atherosclerosis, is the major cause of mortality in systemic lupus erythematosus (SLE) in developed countries. Coronary artery disease and stroke contribute to long-term morbidity in surviving patients. Atherosclerosis in SLE is multifactorial, with immune/i...
What is the current status of trial NCT00120887?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2002-04. Estimated completion is 2005-12.
What conditions does trial NCT00120887 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT00120887?
The interventions under investigation include: Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00120887?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00120887 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of the Herpes Zoster Subunit Vaccine in Lupus
RECRUITING · Phase 4
-
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 4
-
Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
RECRUITING · Phase 4
-
Belimumab Assessment of Safety in SLE
COMPLETED · Phase 4
-
A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
COMPLETED · Phase 4
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.